Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Tennessee Medicaid Gets US Approval For Closed Formulary As Part Of ‘Capped’ Spending Program

Executive Summary

Demonstration, which may not survive scrutiny from the Biden Administration, includes some protections, such as prohibiting Tennessee from excluding drugs described in the Medicare Part D protected classes policy.

You may also be interested in...



Accelerated Approvals In Medicaid: Drug Coverage Exclusion Authority Sought In Oregon

If approved, Oregon would be the first state granted the authority to exclude coverage of accelerated approval drugs, even if manufacturers provide the statutory rebates required for Medicaid.

US Medicaid Director Tsai Proposed Closed Formulary As Head Of Massachusetts Medicaid

Tsai will likely participate in a decision on whether to allow Tennessee to move ahead with changes to its Medicaid program that might include the flexibility to exclude drugs from coverage.

Medicaid Programs Should Be Able To ‘Compel’ Value-Based Contracts, State Association Official Says

Existing value-based contracts, which are voluntary for manufacturers, do not lower costs for states, National Association of Medicaid Directors executive director Matt Salo suggests.

Related Content

Topics

Latest News
UsernamePublicRestriction

Register

PS143575

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel